South African medical cannabis and biotechnology firm Cilo Cybin Holdings has secured major international backing, with Malaysian life sciences investor and scientist Dr. Tham Seng Kong taking a substantial equity stake in the JSE-listed group.
The strategic investment reinforces Cilo Cybin’s balance sheet as the company advances its expansion into commercial-scale medical cannabis production, cellular therapy, and personalized health technologies across regional and global markets.
Strategic Anchor & Capital Injection
Listed on the Johannesburg Stock Exchange’s AltX board, Cilo Cybin originally debuted as a special purpose acquisition company (SPAC) focused on biotech, medical cannabis, and bio-pharmaceutical assets.
Key details of the investment structure include:
• International Backing: The investment, executed via ALPS Global Holding—led by group CEO Dr. Tham Seng Kong—provides Cilo Cybin with pivotal cross-border expertise in genomics, cellular therapies, and precision medicine.
• Regulatory Alignment: The transaction strengthens Cilo Cybin’s position as a public vehicle on the JSE, ensuring compliance with capital requirements and board-level liquidity targets necessary for acquiring operating assets.
• Global Life Sciences Synergy: Beyond capital injection, the deal establishes direct operational linkages between South African bio-manufacturing facilities and Malaysian biotechnology research pipelines.
Targeting Advanced Bio-Pharmaceutical Markets
Founded by Chief Executive Officer Gabriel Theron, Cilo Cybin holds licenses for high-grade medical cannabis processing and is positioning itself to capitalize on global regulatory shifts surrounding alternative therapeutics.
The combined strategy focuses on three core growth vectors:
- Pharmaceutical-Grade Cultivation & Processing: Expanding state-of-the-art indoor cultivation and extraction facilities to supply Good Manufacturing Practice (GMP)-certified cannabis products to European and Australasian markets.
- Genomics & Personalized Medicine: Integrating ALPS’s proprietary DNA profiling and cellular research to develop targeted therapeutic treatments.
- Novel Compounds: Funding ongoing research and development into regulated health products derived from natural active ingredients, including functional mushroom and psychedelic compounds.
Market analysts note that the influx of foreign direct investment into South Africa’s nascent medical cannabis and bio-tech sector highlights growing global demand for high-standard, low-cost African cultivation and manufacturing hubs.
Source: news24.com
